Geron Corporation – LSE:0IV3.L

Add to watchlist

$1.275

-2.02

-61.36%

Market closed

Open in 2 days

-29.94%

month

-29.94%

quarter

+46.67%

year

Market Cap	2.05B
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-0.34

Revenue	520K
EBITDA	-204.46M
Income	-201.39M
Revenue Q/Q	1347.61%
Revenue Y/Y	5.26%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	-39320.77%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Geron Corporation (LSE:0IV3.L): Profit margin
Jun 2023	29K	-49.22M	-169748.28%
Sep 2023	164K	-44.80M	-27320.12%
Dec 2023	23K	-51.97M	-225973.91%
Mar 2024	304K	-55.39M	-18220.39%

Geron Financials Estimate

Q Y

Geron Corporation (LSE:0IV3.L): Analyst Estimates
Mar 2024	304K	-55.39M	-18220.39%
Sep 2025	69.78M	-23.79M	-34.11%
Oct 2025	65.04M	-25.95M	-39.89%
Dec 2025	69.36M	-22.93M	-33.06%

Analysts Price target
Financials & Ratios estimates

Geron Corporation (LSE:0IV3.L): Debt to assets
Jun 2023	415296000	116.86M	28.14%
Sep 2023	413017000	122.40M	29.64%
Dec 2023	394076000	146.12M	37.08%
Mar 2024	482074000	137.20M	28.46%

Geron Corporation (LSE:0IV3.L): Cash Flow
Jun 2023	-29.60M	-44.44M	18.34M
Sep 2023	-50.83M	-4.71M	29.35M
Dec 2023	-40.29M	47.56M	32.64M
Mar 2024	-62.25M	34.20M	147.79M

Geron alternative data

Geron Corporation (LSE:0IV3.L): Employee count
Aug 2023	107
Sep 2023	107
Oct 2023	107
Nov 2023	107
Dec 2023	107
Jan 2024	107
Feb 2024	107
Mar 2024	141
Apr 2024	141
May 2024	141
Jun 2024	141
Jul 2024	141

Status	Patent	Filling date	Issue date
Application	Application Combination Treatment for Hematological Cancers Filling date: 11 Feb 2022 Issue date: 2 Jun 2022	11 Feb 2022	2 Jun 2022
Application	Application SUBCUTANEOUS TELOMERASE INHIBITOR COMPOSITIONS AND METHODS FOR USING SAME Filling date: 15 Jul 2021 Issue date: 2 Jun 2022	15 Jul 2021	2 Jun 2022
Grant	Grant Utility: Process for preparing imetelstat Filling date: 9 Jul 2018 Issue date: 17 May 2022	9 Jul 2018	17 May 2022
Grant	Grant Utility: Oligonucleotide compositions and methods of making the same Filling date: 14 Sep 2017 Issue date: 12 Apr 2022	14 Sep 2017	12 Apr 2022
Grant	Grant Utility: Guanine analogs as telomerase substrates and telomere length affectors Filling date: 7 Feb 2020 Issue date: 22 Mar 2022	7 Feb 2020	22 Mar 2022
Grant	Grant Utility: Combination treatment for hematological cancers Filling date: 28 Jul 2017 Issue date: 22 Mar 2022	28 Jul 2017	22 Mar 2022
Application	Application USE OF A JANUS KINASE INHIBITOR AND A TELOMERASE INHIBITOR FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS Filling date: 3 Nov 2020 Issue date: 2 Sep 2021	3 Nov 2020	2 Sep 2021
Application	Application Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy Filling date: 23 Sep 2020 Issue date: 2 Sep 2021	23 Sep 2020	2 Sep 2021
Application	Application AMORPHOUS SOLID SUCCINYLATED 3-(FATTY ACID AMIDO)-2-HYDROXY-1-(PROTECTED HYDROXY)-PROPANE SALTS AND METHODS OF MAKING THE SAME Filling date: 23 Oct 2020 Issue date: 20 May 2021	23 Oct 2020	20 May 2021
Application	Application CRYSTALLINE SOLIDS OF 3-PALMITOYL-AMIDO-1,2-PROPANEDIOL AND 3-PALMITOYL-AMIDO-2-HYDROXY-1-DIMETHOXYTRIPHENYLMETHYLETHER-PROPANE AND METHODS OF MAKING AND USING THE SAME Filling date: 23 Oct 2020 Issue date: 20 May 2021	23 Oct 2020	20 May 2021

Geron
Executives

Insider	Age	Compensation
Dr. John A. Scarlett (1951) Chief Executive Officer, Pres & Chairman	74	$1,150,000
Dr. Aleksandra Rizo M.D., Ph.D. (1975) Executive Vice President & Chief Medical Officer	50	$968,200
Dr. Andrew J. Grethlein (1964) Executive Vice President & Chief Operating Officer	61	$705,690
Ms. Olivia Kyusuk Bloom (1969) Executive Vice President of Fin., Chief Financial Officer & Treasurer	56	$687,170
Ms. Melissa A. Kelly Behrs (1964) Executive Vice President & Chief Bus. Officer	61	$673,360
Mr. Anil Kapur Chief Commercial Officer & Executive Vice President of Corporation Strategy
Mr. Stephen N. Rosenfield Executive Vice President, Chief Legal Officer & Corporation Sec.
Ms. Suzanne Messere Head of Investor Relations & Corporation Communications
Ms. Shannon Odam Vice President of HR

Frequently Asked Questions (FAQ)

What's the price of Geron stock today?

One share of Geron stock can currently be purchased for approximately $1.28.
When is Geron's next earnings date?

Unfortunately, Geron's (0IV3.L) next earnings date is currently unknown.
Does Geron pay dividends?

No, Geron does not pay dividends.
How much money does Geron make?

Geron has a market capitalization of 2.05B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 60.23% to 237K US dollars.
What is Geron's stock symbol?

Geron Corporation is traded on the LSE under the ticker symbol "0IV3.L".
What is Geron's primary industry?

Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
How do i buy shares of Geron?

Shares of Geron can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Geron's key executives?
Geron's management team includes the following people:
- Dr. John A. Scarlett Chief Executive Officer, Pres & Chairman(age: 74, pay: $1,150,000)
- Dr. Aleksandra Rizo M.D., Ph.D. Executive Vice President & Chief Medical Officer(age: 50, pay: $968,200)
- Dr. Andrew J. Grethlein Executive Vice President & Chief Operating Officer(age: 61, pay: $705,690)
- Ms. Olivia Kyusuk Bloom Executive Vice President of Fin., Chief Financial Officer & Treasurer(age: 56, pay: $687,170)
- Ms. Melissa A. Kelly Behrs Executive Vice President & Chief Bus. Officer(age: 61, pay: $673,360)
- Mr. Anil Kapur Chief Commercial Officer & Executive Vice President of Corporation Strategy
- Mr. Stephen N. Rosenfield Executive Vice President, Chief Legal Officer & Corporation Sec.
- Ms. Suzanne Messere Head of Investor Relations & Corporation Communications
- Ms. Shannon Odam Vice President of HR
How many employees does Geron have?

As Jul 2024, Geron employs 141 workers.
When Geron went public?

Geron Corporation is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
What is Geron's official website?

The official website for Geron is geron.com.
Where are Geron's headquarters?

Geron is headquartered at 919 East Hillsdale Boulevard, Foster City, CA.
How can i contact Geron?

Geron's mailing address is 919 East Hillsdale Boulevard, Foster City, CA and company can be reached via phone at +65 04737700.

Geron Corporation

geron.com

Exchange:

LSE

Full time employees:

141

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

+65 04737700

919 East Hillsdale Boulevard
Foster City, CA 94404

:
ISIN: US3741631036
: